Rising Healthcare R&D And Aging Demographics Will Support Future Success

Published
08 Aug 24
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$98.83
24.1% undervalued intrinsic discount
14 Aug
US$74.98
Loading
1Y
-33.8%
7D
1.5%

Author's Valuation

US$98.8

24.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Decreased 5.42%

Shared on30 Apr 25
Fair value Decreased 12%

AnalystConsensusTarget has decreased revenue growth from 2.3% to 0.7%, decreased profit margin from 14.5% to 12.8% and increased future PE multiple from 49.3x to 54.2x.

Shared on23 Apr 25
Fair value Increased 5.31%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on16 Apr 25
Fair value Decreased 2.04%

AnalystConsensusTarget has increased revenue growth from 2.0% to 2.3%.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 0.31%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 1.45%

AnalystConsensusTarget has decreased revenue growth from 5.2% to 2.0%, increased profit margin from 11.7% to 14.7% and decreased future PE multiple from 59.1x to 51.0x.

Shared on10 Mar 25
Fair value Increased 19%

AnalystConsensusTarget has increased future PE multiple from 34.9x to 59.1x.